Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)
The efficacy and safety of intravenous topotecan (hycamtin) given in a dose of 4 mg/m2 on days of 1, 8, 15 of a 28-day cycle of its therapy were evaluated in patients with recurrent ovarian cancer (OC).Preliminary analysis of the safety and toxicity of the topotecan regimen demonstrated no impact on...
Saved in:
| Main Authors: | E. G. Novikova, I. A. Korneyeva, E. Yu. Moskovskaya |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/152 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014-07-01) -
Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study
by: Tamaki Tanaka, et al.
Published: (2025-06-01) -
Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life
by: E. G. Novikova, et al.
Published: (2014-08-01) -
The role of topotecan in cancer ginecology treatment
by: A. G. Kedrova, et al.
Published: (2017-02-01) -
Deep learning based on ultrasound images to predict platinum resistance in patients with epithelial ovarian cancer
by: Chang Su, et al.
Published: (2025-05-01)